

# The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster

NCT07307976

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Beijing Tiantan Hospital
Enrollment	750 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- \. Ages more than 18 years;
- \. Patients with onset of HZ rash less than 90 days;
- \. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
- \. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
- \. Estimated glomerular filtration rate of 30 mL/min per 1.73 m<sup>2</sup> or higher;
- ... and 1 more (see full listing online)

### Exclusion (5)

- \. History of taking gabapentin or pregabalin;
- \. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;
- \. History of intolerance or hypersensitivity to any active components or excipient of the crisugabalin;
- \. History of systemic immune diseases, organ transplantation, or cancers;
- \. Pregnancy or breastfeeding.

## Locations (1 total)

---

Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing, China